
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data.
In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data.






